Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153164 | 1.00 | CYP19A1 (0.39) | CYP19A1CYP11B1CYP11B2MAOBAKR1B1 | |
| SCHEMBL8348843 | 1.00 | CYP19A1 (0.39) | CYP19A1CYP11B1CYP11B2MAOBAKR1B1 | |
| SCHEMBL13801994 | 0.86 | MAOB (0.35) | CYP19A1MAOBAKR1B1ALDH1A1NR3C1 | |
| SCHEMBL4164629 | 0.85 | AR (0.45) | CYP19A1CYP11B1CYP11B2MAOBAKR1B1 | |
| SCHEMBL4164632 | 0.85 | AR (0.45) | CYP19A1CYP11B1CYP11B2MAOBAKR1B1 | |
| SCHEMBL4160641 | 0.85 | CYP19A1 (0.38) | CYP19A1CYP11B1CYP11B2MAOBAKR1B1 | |
| SCHEMBL4160642 | 0.85 | CYP19A1 (0.38) | CYP19A1CYP11B1CYP11B2MAOBAKR1B1 | |
| SCHEMBL4156234 | 0.84 | NR3C1 (0.46) | CYP19A1CYP11B1CYP11B2MAOBALDH1A1 | |
| SCHEMBL4156231 | 0.84 | NR3C1 (0.46) | CYP19A1CYP11B1CYP11B2MAOBALDH1A1 | |
| SCHEMBL13802889 | 0.79 | NR3C1 (0.62) | CYP19A1CYP11B1CYP11B2MAOBNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | CYP19A1 44/4885CYP11B1 14/4885CYP11B2 15/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | CYP19A1 44/4885CYP11B1 15/4885CYP11B2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.